HLA Monomers as a Tool to Monitor Indirect Allorecognition

Eytan Breman, Paula P. van Miert, Dirk M. van der Steen, Mirjam H. Heemskerk, Ilias I. Doxiadis, Dave Roelen, Frans H. Claas, and Cees van Kooten

Background. Recognition of donor antigens can occur through two separate pathways: the direct pathway (non-self HLA on donor cells) and the indirect pathway (self-restricted presentation of donor derived peptides on recipient cells). Indirect allorecognition is important in the development of humoral rejection; therefore, there is an increasing interest in the monitoring of indirect alloreactive T-cells. We have used an in vitro model to determine the optimal requirements for indirect presentation and assessed the risk for semidirect presentation in this system.

Methods. HLA-typed monocyte-derived dendritic cells (moDCs) were incubated with cellular fragments or necrotic cells and incubated with either indirect or direct alloreactive T-cell clones. T-cell reactivity was measured through proliferation or cytokine secretion. HLA-typed moDC, monocytes, or PBMCs were incubated with HLA class I monomers, in combination with either direct/indirect T-cell clones.

Results. Although both were efficiently taken up, alloreactivity was limited to the semi-direct pathway, as measured by allospecific CD4 (indirect) and CD8 T-cell clones (direct) when cells were used. In contrast, HLA-A2 monomers were not only efficiently taken up but also processed and presented by HLA-typed moDC, monocytes, and PBMCs. Activation was shown by a dose-dependent induction of IFN-γ production and proliferation by the CD4 T-cell clone. Antigen presentation was most efficient when the monomers were cultured for longer periods (24–48 hr) in the presence of the T-cells. Using this method, no reactivity was observed by the CD8 T-cell clone, confirming no semidirect alloreactivity.

Conclusion. We have developed a system that could be used to monitor indirect alloreactive T-cells.

Keywords: Indirect allorecognition, Immune monitoring, HLA, Allopeptide.

Transplantation has become the standard therapy in end-stage renal failure, leading to an increase in quality of life and survival (1). Despite immunosuppressive regimes that are very effective in reducing acute rejection, chronic rejection remains a major cause of allograft loss (2).

T-cells are a major driving force in mediating allograft rejection (3). Recipient CD4+ T-cells can recognize the allograft either through recognition of donor HLA-peptide complexes on donor antigen-presenting cells (APC, direct), or by recognizing self-restricted donor HLA-derived peptides on recipient APCs (indirect). A third pathway (semi-direct) has been postulated in which recipient T-cells recognize intact donor HLA-peptide complexes on recipient APCs (4, 5).

T-cells with direct alloreactivity have been shown to play a dominant role in acute rejection, primarily in the early phase after transplantation, when APCs from donor origin are still available (6–8). T-cells with indirect alloreactivity are correlated with chronic rejection in humans (7, 9, 10). The importance of indirect allorecognition in allograft rejection is multiple and was recently reviewed (11). Briefly, it can provide help...
and thus induce alloreactive cytotoxic CD8 T-cells (12, 13). Perhaps more importantly, indirect alloreactive CD4 T-cells are the only cells that can provide help to alloreactive B-cells as shown in animal models (13–15). These cells have also been implicated in the regulation of tolerance (16). Regulatory T-cells (Treg) from transplant recipients were shown to have indirect alloreactivity (17, 18). Furthermore, they were capable of suppressing both the direct and indirect pathways of allorecognition (19). Animal studies have shown that Treg with indirect allospecificity can abrogate alloantibody formation and mediate transplant tolerance (20–22). Recently, natural Treg were shown to inhibit direct but not indirect allorecognition (23). Although both pathways have been known for decades, assays monitoring indirect T-cell alloreactivity have not become routine, and as of yet, no clinical assay is available (11).

Methods to monitor direct alloreactivity include the mixed leukocyte reaction (MLR), the cytotoxic T-cell precursor assay and more recently, the IFN-α production was observed with concentrations starting at 1 μg/mL HLA-A2 and kept increasing until 125 μg/mL (Fig. 3B). MoDCs were incubated with 25 μg/mL HLA-A2 for various time points, and after extensive washing, 4.44 was added for an additional 24 hr. The highest reactivity was observed when moDCs were incubated for at least 4 hr with the antigen (Fig. 3C). Next, moDCs were incubated with antigen lines (SALs) expressing only HLA-A2 (SAL-A2), T-cell reactivity as measured by IFN-γ was limited to the 1E2 T-cells, confirming specificity of both clones (Fig. 1C).

To investigate the process of indirect alloreactivity, monocyte-derived dendritic cells (moDC) from HLA-typed donors (HLA-DR1+/HLA-A2-) were used as APCs and were loaded with peptides or fragmented SAL-A2 cells as antigen source. After 48 hr, clone 4.44 was added, but apart from the positive control, no indirect alloreactivity could be measured in any of the conditions (Fig. 1D). In contrast, under similar conditions of loading fragments, when clone 1E2 was used, low but significant production of IFN-γ could be detected in three of five experiments (Fig. 1E). This indicates that the use of cell fragments might result in semidirect allorecognition when cocultured with moDC. No reactivity was observed when fragments and 1E2 were cultured alone. 1E2 activation was confirmed in all conditions where viable SAL-A2 were used.

**Processing of Necrotic Cells Leads to Semidirect Allorecognition**

Professional APCs have specialized mechanisms for the uptake of apoptotic or necrotic cells. Therefore, we investigated whether dead cells could be a more efficient way of loading alloantigen, without the risk of semidirect allorecognition. Viable or necrotic SAL-A2 cells were used as previously described (40). HLA-A2 expression on SAL-A2 was confirmed on viable and necrotic (Nec) SAL-A2 (Fig. 2A). Moreover, SAL-A2 were stimulated with IFN-γ to increase HLA-A2 expression on these cells (Fig. 2B). Uptake of dead cells, but not viable cells, was confirmed using flow cytometry as well as confocal microscopy (Fig. 2C–D). Importantly, after 24-hr incubation, a near-complete removal of dead material was observed. This was an active process that did not occur at 4°C.

Indirect allorecognition studies were performed using HLA-A2-/HLA-DR1+ typed moDC. Whereas strong IFN-γ production was achieved with exogenous peptide loading, none of the conditions investigated resulted in detectable activation of the 4.44 clone (Fig. 2E). Activation of moDC using different toll-like receptor (TLR) ligands did not result in detectable indirect presentation (data not shown). Comparable to the fragments, a low albeit significant response was found for semi-direct allorecognition by 1E2 when necrotic SAL-A2 cells were used (Fig. 2F).

**HLA Monomers Can Be Used for Antigen Loading Resulting in Indirect Allopresentation**

As an alternative source of alloantigens, we investigated the potential use of HLA-A2 monomers. Incubation of HLA-DR1+/HLA-A2- moDC with HLA-A2 led to potent activation of clone 4.44 comparable to exogenously loading of peptides (Fig. 3A).

This response was dose dependent, and significant IFN-γ production was observed with concentrations starting at 1 μg/mL HLA-A2 and kept increasing until 125 μg/mL (Fig. 3B).

MoDCs were incubated with 25 μg/mL HLA-A2 for various time points, and after extensive washing, 4.44 was added for an additional 24 hr. The highest reactivity was observed when moDCs were incubated for at least 4 hr with the antigen (Fig. 3C). Next, moDCs were incubated with
HLA-A2 for 4 hr before extensive washing. 4.44 T-cells were then added at 0, 24, or 48 hr and incubated for an additional 24 hr (Fig. 3D). The highest reactivity was observed when 4.44 was added immediately (0 hr), whereas a steady decrease was observed after 24 and 48 hr, indicating a steady turnover of HLA peptide complexes.

Monocytes are the major APCs within the PBMCs; we investigated their capacity to present alloantigens via the indirect pathway. Similar to moDC, monocytes showed a strong capacity to present HLA-A2 and activate 4.44 T-cells, comparable to the exogenous peptide (Fig. 3E). This response was dose dependent, and significant levels of IFN-γ were observed at concentrations of 1 μg/mL HLA-A2, reaching an optimum at 25 μg/mL (Fig. 3F).

PBMCs Can Present Monomer-Derived Peptides to Indirect Allorecognizing T-cells Clones Without Evidence for Semidirect Allorecognition

Because the afore mentioned experiments were performed with purified populations, we next addressed the question whether the use of total PBMC would affect the sensitivity or specificity of the above-described model. HLA-DR1+/HLA-A2- PBMCs were pulsed with HLA-A2 peptides or incubated with HLA-A2 monomers in the presence/absence of 4.44. Again using either exogenous peptide or HLA-A2 monomers, a strong and dose-dependent response of the T-cell clone could be detected (Fig. 4A). In the absence of the T-cell clone, no IFN-γ production could be detected, indicating that the addition of HLA-A2 monomer does not activate CD8 T-cells with direct allospecificity (Fig. 4A). The absence of semi-direct allorecognition could be further confirmed with the 1E2 clone, which was completely unresponsive when incubated with the HLA-typed PBMCs and increasing concentrations of HLA-A2, as depicted by IFN-γ production as well proliferation (Fig. 4C). This is in stark contrast to clone 4.44, which was highly positive in both conditions.

To investigate the sensitivity of this model, various PBMCs concentrations were tested and incubated for 24 or 48 hr with a set amount of HL-A2 and 4.44 (Fig. 4E); 48 hr and 1×10⁵ PBMCs yielded overall a better T-cell response. When titrating the T cell clone, as little as 8 to 40 T-cells were sufficient to induce detectable levels of IFN-γ when 1×10⁵ PBMCs were incubated with 25 μg/mL HLA-A2 for 48 hr (Fig. 4F).
Finally, we could confirm that antigen presentation was completely HLA-DR dependent. The cytokine production and proliferation were completely and dose-dependently prevented when cultures with 4.44 were incubated with a blocking anti-HLA-DR (Fig. 4G).

DISCUSSION
Indirect allorecognition is considered one of the important factors in mediating chronic allograft rejection and influencing long-term graft outcome (7, 41–43). However, at the moment, no reliable test is available to monitor indirect allorecognition in organ transplant recipients. A major hurdle is the antigen loading that requires a high sensitivity to detect low-frequency indirect T-cells and a high specificity to exclude T-cells with direct specificity. In the current study, we have successfully developed a novel in vitro method to measure indirect allorecognition. By using T-cell clones that specifically recognize HLA-A2 through the indirect (HLA-A2 peptides restricted by HLA-DR1) or direct (HLA-A2) pathway of allorecognition, we could demonstrate that semidirect allorecognition is not an issue in our model system, where HLA-A2 monomers were used as a source of alloantigen.

In experiments using HLA-A2 expressing cells as donor antigen source (either as cell fragments or as necrotic cell), reactivity was limited to the semidirect pathway of
alloreactivity. This raises some questions on the conclusions drawn from previous studies that have routinely used cellular fragments to measure indirect alloreactivity (7, 10, 44). Those studies did not include controls to distinguish between semi-direct and indirect allorecognition, and it is therefore possible that the semidirect pathway has a contribution to the allo-recognition measured in those studies.

The semidirect pathway involves the incorporation of alloantigen intact on the cell surface and has been shown to occur with DCs (45), monocytes, and T-cells (46, 47). The process of membrane transfer is a subject of many studies, and the mechanisms involved are now slowly unraveled (48). Interestingly, cross-dressed DCs (DCs that express an acquired HLA-peptide complex) have been shown to prime CD8 T-cells in mice (45, 49). This suggests that semidirect allorecognition could potentially lead to T-cell priming, which is an important factor in interpreting model systems that use cell fragments or apoptotic and necrotic cells to monitor indirect allorecognition. Reactivity against HLA class I molecules was observed in three of five experiments performed. The reactivity was limited to low levels of IFN-γ and is most likely due to the limited HLA class I molecules.
transferred. The conditions in most experiments involving membrane transfer are short term (2 hr); it is possible that longer periods (as used in our experiments) reduce the efficiency and thereby the reactivity. However, we observed no indirect alloreactivity in any of the conditions using cellular fragments or dead cells. Although the material is taken up and processed, there is relatively little HLA class I molecules when compared with all other proteins available that will

![Figure 4](image)

**FIGURE 4.** PBMCs can present HLA-A2 monomer derived peptides via HLA-DR1 with no measurable semi-direct alloreactivity. A-B, 1 × 10^5 Typed HLA-DR1+/HLA-A2- PBMCs were incubated with different concentrations of HLA-A2 monomers or pulsed with an HLA-A2 peptide and cocultured with or without 5 × 10^5 4.44 T-cells; 48 hr after incubation, supernatants were collected and IFN-γ measured. C-D, PBMCs were incubated with different concentrations of HLA-A2 monomers and cocultured with either the indirect recognizing clone 4.44 (gray circles) or with the direct recognizing clone 1E2 (white circles) for 48 hr. IFN-γ and proliferation were analyzed as previously described. E, Different PBMC numbers were incubated with 25 μg/mL HLA-A2 in the presence of 5 × 10^5 4.44 for 24 or 48 hr. Supernatants were then harvested and IFN-γ measured. F, To test the minimal amount of T-cells needed to detect a response, 4.44 were titrated, and 25 μg/mL HLA-A2 monomer was added in combination with 1 × 10^5 HLA-typed PBMCs for 48 hr. Supernatants were then collected and IFN-γ measured. G-H, PBMCs were cocultured with 4.44 T-cells in the presence of 25 μg/mL HLA-A2 for 24 hr with or without anti-HLA-DR monoclonal antibodies (mAb). The reciprocal dilution of the HLA-DR mAb is set on the x-axis. All experiments were conducted at least three times. Shown is the mean±SD of one experiment in triplicate. Dashed line represents the detection limit of the ELISA used. ND, not detectable.
also be processed and presented and therefore will generate large amounts of competing peptides that will not be recognized by the T cell clone.

Another strategy to monitor indirect presentation has been the use of synthetic peptides. In vivo APCs present donor-derived peptides to autologous T-cells restricted by their own HLA class II molecules. Each HLA class II molecule has its own repertoire of peptides that can be presented. Prediction of HLA class II epitopes is complex, and it is unlikely that a set of peptides can be used to predict individual alloreactivity (50). Current tests that use synthetic peptides have the risk of creating neo-epitopes, epitopes that are not created in the natural antigen processing manner (31–33, 51). This may even lead to reactivity to peptides derived from autologous HLA molecules. Peptides used for the detection of indirect allorecognition include peptides derived from the β1 domain of HLA class II (32, 51–53) or the α1 domain of HLA class I (33, 54). In one study, where peptides from a complete HLA-A2 molecule were used, reactivity was seen in the hypervariable region as well as from the α3 subunit and the transmembrane domain (52). However, as no peptides from self-HLA were taken as a control, it is unclear what the reactivity means and whether these peptides would be formed when naturally processed. Use of longer peptides could be a good alternative, as these would require processing and are able to induce T-cell reactivity in other model systems of antigen presentation (53, 54).

HLA monomers offer solutions to many of the problems depicted earlier. However, there are two distinct disadvantages in using monomers. The one is the high price involved in making highly pure monomers and, second, the relatively high concentration needed to induce a reproducible T-cell response. The quest to induce long-term graft tolerance and/or survival starts with an accurate depiction of the recipient’s immune response against the donor allograft. Although many studies are aimed at monitoring and measuring operational tolerance and organ rejection (55, 56), no reliable test exists other than the actual clinical outcome. Measuring indirect allorecognition could give a broad view into how the recipient immune system is shaping its response to the allograft and be helpful in tailoring an individual immune-suppression regime to prolong graft survival.

**MATERIALS AND METHODS**

**Cell Culture and Reagents**

Peripheral blood mononuclear cells (PBMCs), monocytes, and monocytederived dendritic cells (moDCs) were cultured in RPMI-1640 (PAA, Austria) supplemented with 10% FCS (Bodinco, The Netherlands), 5,000 U/mL penicillin, and 5 mg/mL streptomycin (Invitrogen, USA).

Single antigen lines (SAL) were created by transfecting K562 cells with a plasmid construct containing a HLA-A2 heavy chain gene (SAL-A2) (57). SAL-A2 were maintained in IMDM medium supplemented with 10% FCS, pen/strep, and G-418 (Roche, Germany) at a concentration of 250 µg/mL for the selection of stably transfected SALs.

HLA-A*0201–derived peptides of the region 99-122 of HLA-A2 were synthesized. HLA-A*0201 heavy chains were produced in *Escherichia coli*. Monomer refolding around the melanoma-associated pmd17 peptide (YLPVGVTIA) in the presence of β2-microglobulin was achieved as previously described (38). Monomers were purified gel filtration HPLC and tested routinely.

T-cell clones 4.44 (CD4+) and 1E2 (CD8+), recognizing HLA-A2 (aa98–120) restricted by HLA-DR1 and HLA-A2, respectively, have been previously described (38, 39). They were maintained in IMDM medium (PAA, Austria) with 5% FCS (Bodinco, The Netherlands), 5% normal human serum (Sanquin, The Netherlands), 100 IU/mL recombinant IL-2 (Chiron, Novartis, USA), 5,000 U/mL penicillin, 5 mg/mL streptomycin, and 2 mM L-glutamine (Gibco, Invitrogen, USA). Expansion was achieved by stimulation with phytohemagglutinin (PHA, 0.8 µg/mL, Murex Biotec Limited, Dartford, UK) and PBMCs in a ratio of 1:5. Cells were harvested after 2 weeks and either frozen or used in experiments after a resting period of 2 to 3 days. T-cell specificity was routinely tested.

Stable EBV-transformed B-cell lines (EBV-LCL) were generated from an HLA-DR1+/HLA-A2- donor using standard procedures (60). HLA-A2+ EBV-LCLs were generated by transducing a retroviral vector encoding for HLA-A*0201 into the donor (HLA-A2-) EBV-LCLs (61).

**Generation of Monocyte-Derived Dendritic Cells**

moDCs were generated from buffy coats as previously described (62). Briefly, PBMCs were isolated from buffy coats (Sanquin, The Netherlands) of healthy (HLA-A2+ ,HLA-DR1+) individuals using Ficoll/amidotrizoate (pharmacy, LUMC, The Netherlands) density gradient, followed by CD14 microbeads magnetic cell sorting (Miltenyi Biotec, The Netherlands) according to the manufacturer’s protocol. Monocytes were cultured in six-well plates (Costar, USA) in RPMI-1640 supplemented with 10 ng/mL IL-4 and 5 ng/mL GM-CSF (Gibco, Invitrogen, USA). Cytokines were refreshed every 2 to 3 days, and cells were allowed to differentiate for at least 6 days before harvesting.

**Indirect Allorecognition Assay Using Cells as Source of HLA Class I Antigens**

moDCs were cocultured with necrotic, apoptotic, or fragmented SAL-A2 cells. Necrosis and apoptosis was induced as previously described (40). Briefly, necrosis was induced by heating cells to 36°C for 1 hr and confirmed using light microscopy. Necrotic cells were washed three times with 10 µg/mL PI staining. Cell fragments were generated by freeze-thawing and confirmed using light microscopy. Five × 10^4 moDCs were cocultured at a 1:1 ratio with SAL-A2 cells for a period of at least 24 hr in a 96-well plate and 5 × 10^4 4.44 (CD4 indirect) or 1E2 (CD8 direct/semidirect) cells were added for an additional 48-hr incubation. Supernatants were then harvested, and IFN-γ production was measured.

**Phagocytosis Assay**

Phagocytosis was quantified using flow cytometry or fluorescence microscopy as previously described (40). Briefly, moDCs were labeled with PKH26 (Sigma-Aldrich) or stained with HLA-DR mAb. Necrotic, apoptotic, or fragmented SAL-A2 cells were stained with CFSE before induction of cell death and then cocultured with moDCs at a ratio of 1:1 (5 × 10^5 cells). Analysis was conducted at 2 or 24 hr post coculture. Fluorescence was assessed with FACSCalibur or LSR-II or with a Leica SP5 confocal scanning laser microscope, and the analysis performed with ImageJ imaging software.

**Indirect/Direct Allorecognition Assay Using HLA Class I Monomers**

To monitor the pathways of allorecognition moDC or monocytes (DR1+/A2-) were plated (3 × 10^5) in round 96-well plates (Costar, USA) and incubated with different concentrations of HLA-A2 monomers (HLA-A2) or peptides. T-cells were added to the culture and incubated at different time points. A CD4 T-cell clone (5 × 10^5, 4.44) was used as a readout for indirect allorecognition and a CD8 T-cell clone (5 × 10^5, 1E2) for direct/semidirect allorecognition. Part of the supernatant was harvested, and cells were pulsed with 0.5 µCi ³H (Life Science Products, Inc., USA) and incubated for 24 hr. Similarly, (1 × 10^5) PBMCs were cocultured with (5 × 10^5) T-cells (4.44 or 1E2) with different concentrations of HLA-A2. Cytokines were incubated for 48 hr, supernatants collected, and cells pulsed with ³H for another 24 hr when proliferation was measured. Inhibition of indirect allorecognition was achieved by titration of mouse antihuman HLA-DR (B8.11.2, IgG2b) antibodies to the cocultures.
ACKNOWLEDGMENTS

The authors thank Dr. Hetty de Boer from the Department of Nephrology of the Leiden University Medical Centre, for providing help in confocal imaging.

REFERENCES

1. Doyle AM, Lechler RJ, Turka LA. Organ transplantation: halfway through the first century. *J Am Soc Nephrol* 2004; 15: 2965.

2. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. *N Engl J Med* 2010; 363: 1451.

3. Afzali B, Lombardi G, Lechler RI. Pathways of histocompatibility complex allore cognition. *Curr Opin Organ Transplant* 2008; 13: 438.

4. Tsang JY, Chai JG, Lechler R. Antigen presentation by mouse C4D+ T cells involving acquired MHC class I peptide complexes: another mechanism to limit clonal expansion? *Blood* 2003; 101: 2704.

5. Huang JP, Yang Y, Sepulveda H, et al. TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. *Science* 1999; 286: 952.

6. Hornick PI, Mason PD, Yacoub MH, et al. Assessment of the contribution that direct allore cognition makes to the progression of chronic cardiac transplant rejection in humans. *Circulation* 1998; 97: 1257.

7. Baker RJ, Hernandez-Fuentes MP, Brooks PA, et al. Loss of direct and maintenance of indirect allose responses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. *J Immunol* 2001; 167: 7199.

8. Smith C, Miles JJ, Khanna R. Advances in direct T-cell allore cognition: function, avidity, biophysics and structure. *Am J Transplant* 2012; 12: 15.

9. Brennan TV, Jagirdar A, Hoang V, et al. Preferential priming of alloreactive T cells with indirect reactivity. *Am J Transplant* 2009; 9: 709.

10. Hornick PI, Mason PD, Baker RJ, et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. *Circulation* 2000; 101: 2405.

11. Ali JM, Bolton EM, Bradley JA, et al. Allorecognition pathways in transplant rejection and tolerance. *Transplantation* 2013; 96: 681.

12. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. *Nature* 1998; 393: 474.

13. Taylor AL, Negus SI, Negus M, et al. Pathways of helper CD4 T cell allore cognition in generating alloantibody and CD8 T cell alloimmunity. *Transplantation* 2007; 83: 931.

14. Conlon TM, Saeh-Parys K, Cole JL, et al. Germinal center allose responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. *J Immunol* 2012; 188: 2643.

15. Steele DJ, Laфер TM, Smiley ST, et al. Two levels of help for B cell alloantibody production. *J Exp Med* 1996; 183: 699.

16. Salama AD, Najafian N, Clarkson MR, et al. Regulatory CD25+ T cells in human kidney transplant recipients. *J Am Soc Nephrol* 2003; 14: 1643.

17. Jiang S, Tsang J, Game DS, et al. Generation and expansion of human CD4+CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. *Transplantation* 2006; 82: 1738.

18. Xu Q, Lee J, Keller M, et al. Analysis of indirect pathway CD4+ T cells in a patient with metastable tolerance to a kidney allograft: possible relevance to superior graft survival of HLA class II closely matched renal allografts. *Transpl Immunol* 2009; 20: 203.

19. Spadadora-Ferreira M, Caldas C, Fae KC, et al. CD4+CD25+Foxp3+ indirect alloreactive T cells from renal transplant patients suppress both the direct and indirect pathways of allore cognition. *Scand J Immunol* 2007; 66: 352.

20. Callaghan C, Roubani FJ, Negus GC, et al. Abrogation of antibody-mediated allore cognition by regulatory CD4 T cells with indirect allospecificity. *J Immunol* 2007; 178: 2221.

21. Tanriver Y, Ratnasothy K, Bucy RP, et al. Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allore cognition and the production of IgG allose antibodies leading to long-term allograft survival. *J Immunol* 2010; 184: 1757.

22. Tsang JY, Tanriver Y, Jiang S, et al. Indefinite mouse heart allograft survival in recipient treated with CD4+(+)/CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. *Transpl Immunol* 2009; 21: 203.

23. Noel G, Belghith M, Belanger B, et al. Direct allore cognition is more susceptible to regulation by natural regulatory T cells than indirect allore cognition. *J Immunol* 2013; 190: 3764.

24. Roelen DL, Stobbe I, Young NT, et al. Permissible and immunogenic HLA-A mismatches: cytotoxic T-cell precursor frequencies reflect graft survival data. *Hum Immunol* 2001; 62: 661.

25. Bach F, Hirschhorn K. Lymphocyte interaction: a potential histo-compatibility test in vitro. *Science* 1964; 143: 813.

26. Bestard O, Crespo E, Stein M, et al. Cross-validation of IFN-gamma Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. *Am J Transplant* 2013; 13: 1880.

27. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. *Am J Transplant* 2003; 3: 878.

28. Waanders MM, Heidt S, Koekkooi KM, et al. Monitoring of indirect allore cognition: wishful thinking or solid data? *Tissue Antigens* 2008; 71: 1.

29. Bedford P, Garner K, Knight SC. MHC class II molecules transferred between allologenic dendritic cells stimulate primary mixed leucocyte reactions. *Int Immunol* 1999; 11: 1739.

30. Sivagnesan S, Harper SJ, Conlon TM, et al. Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells. *J Immunol* 2013; 190: 5829.

31. Illigens BM, Yamada A, Anosova N, et al. Dual effects of the allore cognition by Th1 and Th2 cells on acute and chronic rejection of allografts. *Eur J Immunol* 2009; 39: 3008.

32. Reznik SI, Jaramillo A, Sivaisi KS, et al. Indirect allore cognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. *Am J Transplant* 2001; 1: 228.

33. Stegmann S, Muller A, Zavazava N. Synthetic HLA-A2 derived peptides are recognized and presented in renal graft recipients. *Hum Immunol* 2000; 61: 1363.

34. Carrodouglas A, Orosz CG, Waldman WJ, et al. Trans vivo analysis of human delayed-type hypersensitivity reactivity. *Hum Immunol* 1999; 60: 640.

35. VanBuskirk AM, Burlington WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. *J Clin Invest* 2000; 106: 145.

36. Haynes LD, Jankowska-Gan E, Sheka A, et al. Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. *Am J Transplant* 2012; 12: 640.

37. Warnecke G, Chapman SJ, Bushell A, et al. Dependency of the trans vivo delayed type hypersensitivity response on the action of regulatory T cells: implications for monitoring transplant tolerance. *Transplantation* 2007; 84: 392.

38. Amir AL, Hagedoorn RS, van Luxemburg-Heijis SA, et al. Identification of a coordinated CD8 and CD4 T cell reponse directed against mismatched HLA class I causing severe acute graft-versus-host disease. *Biol Blood Marrow Transplant* 2011; 18: 9.

39. Horai S, van der Poel J, Goulmy E. Differential recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. *J Population studies. Immunogenetics* 1982; 16: 135.

40. Xu W, Roos A, Schlagwein N, et al. IL-10-producing macrophages preferentially clear early apoptotic cells. *Blood* 2006; 107: 4930.

41. Ballet C, Renaudin K, Degauque N, et al. Indirect CD4+ T cell reponse, antidonor antibodies and diffuse C4d graft deposits in long-term recipients conditioned by donor antigens priming. *Am J Transplant* 2009; 9: 697.

42. Boisgerault F, Liu Y, Anosova N, et al. Differential roles of direct and indirect allore cognition pathways in the rejection of skin and corneal transplants. *Transplantation* 2009; 87: 16.

43. Gokmen MR, Lombardi G, Lechler RI. The importance of the indirect pathway of allore cognition in clinical transplantation. *Curr Opin Immunol* 2008; 20: 568.

44. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. *Am J Nephrol* 2008; 19: 1419.

45. Smyth LA, Hervouet C, Hayday T, et al. Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo. *J Immunol* 2012; 189: 2274.

46. HoWangYin KY, Alegre E, Daouya M, et al. Different functional outcomes of intercellular membrane transfers to monocytes and T cells. *Cell Mol Life Sci* 2010; 67: 1133.
47. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. *Nature* 2001; 411: 489.

48. Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. *J Cell Mol Med* 2011; 15: 1458.

49. Li L, Kim S, Herndon JM, et al. Cross-dressed CD8alpha+/CD103+ dendritic cells prime CD8+ T cells following vaccination. *Proc Natl Acad Sci U S A* 2012; 109: 12716.

50. Lin HH, Zhang GL, Tongchusak S, et al. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. *BMC Bioinformatics* 2008; 9(Suppl 12): S22.

51. Najafian N, Salama AD, Fedoseyeva EV, et al. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. *J Am Soc Nephrol* 2002; 13: 252.

52. Harnesakul R, Maillere B, Briggs D, et al. Indirect recognition of T-cell epitopes derived from the alpha 3 and transmembrane domain of HLA-A2. *Am J Transplant* 2007; 7: 1148.

53. Harnesakul R, Maille B, Valentinj AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clin Cancer Res* 2008; 14: 169.

54. Rosario M, Bridgerman A, Quakkelraed ED, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. *Eur J Immunol* 2010; 40: 1973.

55. Turka LA, Lechler RI. Towards the identification of biomarkers of transplantation tolerance. *Nat Rev Immunol* 2009; 9: 521.

56. Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation—how much of the promise has been realized? *Nat Med* 2005; 11: 605.

57. Zee YM, Eijssink C, Kardol MJ, et al. The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. *Hum Immunol* 2005; 66: 519.

58. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. *Science* 1996; 274: 94.

59. van der Poel JJ, Pool J, Goulmy E, et al. Recognition of distinct epitopes on the HLA-A2 antigen by cytotoxic T lymphocytes. *Hum Immunol* 1986; 16: 247.

60. Heemskerk MH, Heuverberg E, Ruizedal JJ, et al. Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells. *Cell Immunol* 1999; 195: 10.

61. Heemskerk MH, de Paus RA, Lurvink EG, et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. *Proc Natl Acad Sci U S A* 2001; 98: 6806.

62. Wolfsman AM, de Fijter JW, Kamerling SW, et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. *Eur J Immunol* 2000; 30: 1807.